The medical technology (Medtech) sector experienced a challenging year characterized by stock market volatility and inflation rates, alongside ongoing discussions about the impacts of artificial intelligence. Despite this, merger and acquisition (M&A) deals recorded remarkable growth driven by a limited number of major multi-billion-dollar deals, according to the Pulse of the Industry report issued by Ernst & Young (EY).
A Surge in Mega-Deals in the Medtech Sector
The value of announced deals in the medtech sector reached approximately $130 billion during the 12-month period ending June 30, which is more than three times the $39 billion recorded in the same period of the previous year, reaching its highest level in more than a decade. The list was led by major deals valued at around $10 billion or more each, including Waters' acquisition of BD's diagnostics and biosciences businesses for $17.5 billion in February, Abbott's acquisition of Exact Sciences for $21 billion in March, Danaher's purchase of Masimo for $9.9 billion in June, and Boston Scientific's pending acquisition of Penumbra for $15.2 billion.
Continuation of Spin-off and Divestiture Strategies
Medical device companies continued to rely on the strategy of spin-offs and divestitures as a tool to reorganize their investment portfolios. This included the initial public offering of Medtronic's MiniMed diabetes unit as an independent company in March, alongside J&J's plans to spin off or divest its orthopedics unit, and Abbott's announcement of plans to spin off its nutrition business. John Babitt, EY's Global Medtech Leader, noted that merely announcing a spin-off does not necessarily guarantee the creation of value for shareholders, but rather requires finding the right buyer.
Declining Market Valuations and Slower Growth Expectations
In contrast to deal growth, company valuations declined by nearly 10% in the first half of 2026 compared to the previous year, bringing the total market capitalization of companies to $1.58 trillion. Babitt attributed part of this to the flow of capital toward artificial intelligence and general technologies, in addition to major companies like Boston Scientific and Abbott lowering their sales growth forecasts for 2026, suggesting slower growth rates by the end of the year.
What This Means for Investors and Markets
Despite challenges related to valuations and lower earnings estimates, capital continues to flow into emerging and advanced sectors, such as robotics and brain-computer interface companies. Investors are also focusing on medical procedures that serve as alternatives to drugs, such as renal denervation technologies to treat high blood pressure and innovation in tumor ablation surgeries to treat cancer.